&w=3840&q=100)
Xi Jinping's price-war campaign creates a buzz in China's stock market
Bloomberg
Bloomberg News
For strategists at JPMorgan Chase & Co. and Goldman Sachs Group Inc. as well as money managers in Hong Kong and Singapore, an opaque term has suddenly emerged as the catchphrase for deciphering Chinese policy intentions and navigating the stock market.
The term 'anti-involution' has cropped up in government documents over the past year, but gained prominence earlier this month when President Xi Jinping chaired a high-level meeting that pledged to regulate 'disorderly' price competition. It refers to efforts to root out China's industrial malaise, marked by cutthroat price wars and overcapacity that have hurt profitability in sectors ranging from solar, new energy vehicles to steel.
Investors are hopeful that a more coordinated policy response to tackle the drivers of deflation is on its way, though Beijing hasn't yet released any plan. Analyst reports on the theme have flooded the market, while solar and steel stocks have rallied in July. Morgan Stanley strategists changed their preference to onshore shares from those in Hong Kong last week.
'One of the biggest issues that investors have investing in China is that of excessive competition,' said Min Lan Tan, head of the Asia Pacific chief investment office at UBS AG. 'It's actually a very positive development that top down the government is now recognizing it and directly saying that destructive competition has to stop. It's a powerful policy signal.'
The Chinese term for involution, 内卷 (neijuan), literally means rolling inwards. In practice, it's used to describe a system of intense competition that yields little meaningful progress.
Huge spending on building capacity has helped Chinese firms enhance their global standing. The nation's companies now dominate every step of the solar supply chain, while its EV makers have toppled Tesla's dominance. Yet, ending destructive competition has rarely been more important. Producer deflation is worsening, and trade tensions mean China can no longer unleash some of its overcapacity to other countries.
'With foreign markets closing off Chinese trade routes, part of the competition is forced to return to the domestic market,' said Jasmine Duan, senior investment strategist at RBC Wealth Management Asia.
The campaign seems to be helping improve investor sentiment for the mainland market, where policy drivers have a stronger sway and industrial stocks have bigger weighting. The onshore CSI 300 Index has risen 2% so far in July, outperforming the Hang Seng China Enterprises Index after lagging it for most of the year.
Solar stocks Xinjiang Daqo New Energy Co. and Tongwei Co. have advanced at least 19% this month. Liuzhou Iron & Steel Co Ltd. has surged more than 50% while Angang Steel Co. has gained about 16%. Glass, cement and chemicals shares have also jumped.
It's still early stages but if the reforms pan out, 'there'll be consolidation in China and there'll be slightly better pricing and margins, and there'll be better valuation,' said Wendy Liu, head of China and Hong Kong equity strategist at JPMorgan. Sectors that are likely to benefit include autos, battery, solar, cement, steel, aluminum and chemicals, she said.
To seasoned China watchers, the current rhetoric recalls the supply-side reforms of 2015-2018, when a government-led push to cut outdated capacity in sectors such as coal and steel helped drive up prices in the following years.
This time, however, key differences may limit the campaign's effectiveness. A decade ago, oversupply was mostly concentrated in upstream and construction-related sectors. It's become more pervasive today, encompassing the most promising industries of solar, EV and battery to downstream consumer sectors such healthcare and food.
That point is illustrated by the intensifying price war among technology giants listed in Hong Kong — China's private sector leaders. Shares in Meituan, Alibaba Group Holding Ltd. and JD.com Inc. have slumped more than 20% from their March highs as they jostle for delivery market expansion.
'This time the overcapacity is concentrated in industries mostly dominated by private firms, so the challenges are going to be greater than when SOEs ruled and could just buy up the private firms and shut them down,' said Li Shouqiang, a fund manager at Shenzhen JM Investment Management.
Addressing the supply-demand imbalance will also require measures to reflate the economy by boosting consumption — a tall order the government has struggled to deliver on.
For now, investors seem hopeful that a bigger supply-side reform is in the offing. Morgan Stanley strategists said sentiment has improved with the government's message, and added they now prefer A-shares over offshore ones.
'When senior policymakers change some policy tone, there should be some actionable items or something to follow through,' said Louisa Fok, China equity strategist with Bank of Singapore. It won't be a quick overnight fix, but it's 'definitely positive' that the government is aware of the problems, she added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Hindu
32 minutes ago
- The Hindu
Jaishankar urges ‘continued normalisation' of ties between India and China
External Affairs Minister S. Jaishankar in China on Monday (July 14, 2025) called for 'continued normalisation' of ties between India and China when he met Chinese Vice President Han Zheng. In his first visit since the 2020 military standoff along the Line of Actual Control (LAC) in eastern Ladakh, Mr. Jaishankar said the resumption of the Kailash Mansarovar Yatra is 'widely appreciated in India'. Six years after the last Kailash Mansarovar yatra (pilgrimage) was held, the journy was restarted recently last month. 'It is a pleasure to be with you during my visit for the Shanghai Cooperation Organisation (SCO) Foreign Ministers meeting. India supports a successful Chinese presidency at the SCO,' he said. The External Affairs Minister also said the bilateral relationship between India and China has been steadily improving since the meeting between Prime Minister Modi and President Xi Jinping in Kazan last October. 'I am confident that my discussions in this visit will maintain that positive trajectory,' he added. The international situation is very complex. As neighbouring nations and major economies, an open exchange of views and perspectives between India and China is very important, Mr. Jaishankar said. The Meeting of the Council of the Ministers of Foreign Affairs of the SCO will be held in Tianjin on July 15. The SCO comprises 10 member states — China, Russia, India, Iran, Kazakhstan, Kyrgyzstan, Pakistan, Tajikistan, Uzbekistan and Belarus. Mr. Jaishankar's visit follows the recent visits of Defence Minister Rajnath Singh and National Security Advisor Ajit Doval to China. China is the current chair of the SCO and it is hosting the meetings of the grouping in that capacity.
&w=3840&q=100)

Business Standard
36 minutes ago
- Business Standard
China's biotech surge shifts global drug innovation, stirs US tension
By Amber Tong, Jinshan Hong and Spe Chen The biotechnology industry is experiencing a tectonic shift, driven by Chinese drugmakers who have come a long way from their copycat days to challenge Western dominance on innovation. The number of novel drugs in China — for cancer, weight-loss and more — entering into development ballooned to over 1,250 last year, far surpassing the European Union and nearly catching up to the US's count of about 1,440, an exclusive Bloomberg News analysis showed. And the drug candidates from the land once notorious for cheap knock-offs and quality issues are increasingly clearing high bars to win recognition from both drug regulators and Western pharmaceutical giants. The findings, gleaned from an analysis of a database maintained by pharma intelligence solutions provider Norstella, show a fundamental shift in medical innovation's center of gravity. With President Donald Trump already threatening tariffs on the pharmaceutical sector, China's biotech advances — the scale of which is slowly coming into view — risk becoming another realm of superpower rivalry like artificial intelligence and electric vehicles. 'The scale itself is not something we've seen before,' said Helen Chen, managing partner at LEK Consulting in Shanghai, who has advised healthcare companies on their China strategy since 2003. 'The products are here, they're attractive and they're fast.' This shift has occurred at an unprecedented pace. When China began to overhaul its drug regulatory system in 2015, the country had just 160 compounds to contribute to the global pipeline of innovative drugs, or less than 6% of the total, behind Japan and the UK. The reforms helped streamline reviews, enforced data quality standards and improved transparency. The government's 'Made in China 2025' plan to elevate manufacturing in 10 priority sectors also helped spur a flurry of investments in biotechnology. Altogether, they unleashed a boom led by foreign-educated and -trained scientists and entrepreneurs. 'Not only is it now almost at parity with the US but it has that growth trajectory,' said Daniel Chancellor, vice president of thought leadership at Norstella. 'It wouldn't be sensationalist to suggest that China will overtake the US in the next few years purely in terms of numbers of drugs that it's bringing through into its pipeline.' Bloomberg News ' data analysis focuses on innovative drugs, excluding generic combinations, reformulations and biosimilars. Numbers aside, the more stunning leap is in the quality of Chinese biotech innovation. While there's constant debate in the pharmaceutical industry on whether Chinese firms are capable of producing not just effective but needle-shifting new therapies, there's growing recognition on multiple fronts. The world's strictest regulatory agencies, including the US Food and Drug Administration and the European Medicines Agency, increasingly view Chinese drugs as generally promising enough to justify devoting extra resources to speed up their review, handing them coveted industry designations such as priority review, breakthrough therapy designation or fast track status. The country is now slightly ahead of the EU in earning such expedited reviews as of 2024, the data shows, a remarkable edge over a region that previously produced drugs like Wegovy. One of the early exemplars of Chinese innovation is a cell therapy that has shown promise to potentially cure a deadly blood cancer. First developed in China by Legend Biotech Corp, it is now marketed by Johnson & Johnson — having won a few expedited review designations along the way — and considered superior to a competing US-originated therapy. Still, the absolute number of China-originated drugs winning these designations trail their US counterparts by a large margin. Risk-aversion remains a factor holding back Chinese pharmaceutical innovation: So far, top companies tend to focus on making better versions of existing therapies or new iterations of older ideas, and few are pioneering novel treatment approaches that have never been tried before — an endeavor that comes with a high risk of failure and is still led by the US, Europe and, to a lesser extent, Japan. Nevertheless, the biggest Chinese breakthroughs are increasingly being snapped up by pharmaceutical giants for record sums, a sign that the perennial competition for the next blockbuster drug is also shifting East. A novel cancer drug from Akeso Inc., which came out more effective than Merck & Co Inc.'s Keytruda in a Chinese study last year, has been likened to China biotech's DeepSeek moment, spawning a new wave of global interest. The promise of topping Keytruda, the world's top-selling drug, also swelled the valuation of Summit Therapeutics Inc, which in 2022 paid $500 million upfront for the development and marketing rights in the US and other regions. Other multinational players like Merck, AstraZeneca Plc and Roche Holding AG have also scooped up Chinese assets. In May, Pfizer Inc. set a new record as it announced a $1.2 billion upfront deal with 3SBio Inc. for a cancer drug similar to Akeso's. These deals are increasing in both value and frequency, according to biopharma deal database DealForma, signaling confidence that China-originated drugs are competitive internationally and can bring in substantial revenue. The volume of potential candidates coming out of China means multinational companies, who have a constant need to add new products to the mix, can 'cast their net wider than ever before,' Norstella's Chancellor said. A key advantage that has fueled the rise of Chinese biotech firms is their ability to conduct research cheaper and faster at every step of the way, from lab experiments and animal testing to human trials. Creating a new drug from scratch is notoriously time-consuming and expensive, and China's massive patient pool and centralized hospital network have become a significant accelerator. An analysis of the time taken for drugs to conduct various testing stages shows that doctors in China can recruit for trials much faster — for early trials for cancer and obesity drugs, they can complete patient enrollment in half the time compared to the US. The difference in costs means Chinese companies can afford to run multiple trials simultaneously to find a winner, or quickly launch new projects once a scientific idea is validated by other groups. Since 2021, China has become the top location for clinical research, initiating the largest number of new trials globally, according to GlobalData. 'They can leapfrog competitors in other countries,' said Andy Liu, head of China at Novotech Health Holdings, which helps companies run clinical trials. To be sure, clinical data in China is just a start. US regulators have made it clear that China-only trial results, no matter how positive, are not sufficient to support drug approvals. Chinese biotechs with ambition to sell their drugs overseas must prove that their treatment benefits can be replicated in non-Chinese patients, through complex and slower-moving global studies. It may still be a few years before a critical mass of drugs sourced from China wins US and EU approvals — the gold standard for high-quality treatments — and become widely used in the Western world, but many in the industry believe that's inevitable. China's innovators comprise both cutting-edge biotech startups founded by foreign-educated entrepreneurs, and old-guard Chinese pharmaceutical companies like Jiangsu Hengrui Pharmaceuticals Co., which used to be one of the country's biggest generic drugmakers. The company poured billions of dollars into shifting to innovative research and development after Beijing's campaign to lower generic drug prices made that sector less profitable. It's now the world's top-ranked pharmaceutical company for the number of new innovative drugs added to the research pipeline in the period of 2020-2024. Of the 50 companies that generated the highest number of innovative drug candidates between 2020 and 2024, 20 of them were Chinese, compared to five in the five years before. 'As we move forward, the fact that there's high quality innovation in China in terms of biotech will no longer be a novelty,' said Ali Pashazadeh, founder and managing director of healthcare advisory firm Treehill Partners in London. 'It'll just be an accepted part of the norm.' At a time when China and the US are engaged in renewed geopolitical spats, the growth of China's biotech ecosystem is causing alarm among some American politicians and business leaders. A congressional commission warned that the US risks losing its leadership position in yet another industry critical to national security. 'Biotech is one of the forefronts of the US-China tech rivalry,' said Jack Burnham, research analyst at the think tank Foundation for Defense of Democracies. In addition to economic implications and possible military applications of biotech, China's leverage on innovative therapies may be weaponized in a future conflict, he said, if Americans become dependent on those medicines. The perception of threat has spurred calls for the US government to stymie China's biotech growth — through restrictions such as export controls on scientific equipment and barriers to investment — and boost the domestic biotech sector, including by changing the regulatory environment to emulate countries where clinical trials are run more quickly. Robert F. Kennedy, the US Secretary of Health and Human Services, recently pledged to 'Make American Biotech Accelerate.' Despite the risks of the newly combative relationship between the world's two biggest economies, Chinese drugmakers like Akeso have set their sights on bringing their therapies to developed Western markets. 'The pharma industry is the best industry in the world,' Akeso Chief Executive Officer Michelle Xia said in an April interview. 'At the end of the day, what we do benefits patients in China, in the US and all around the world.'


Mint
an hour ago
- Mint
EU Official Says Bloc to Explore Asia Pacts as US Tariffs Loom
The European Union is looking to deepen trade agreements with India and other countries in the Asia-Pacific region as the bloc braces for US tariffs, a top official said. 'We need to explore how far, how deep we can go in the Pacific area with other countries,' EU competition chief Teresa Ribera said on Bloomberg TV on Monday. 'For instance, these conversations that are ongoing with India are quite important,' she said, referring to free-trade talks with the South Asian nation expected to be completed by year's end. The EU is preparing to step up its engagement with other countries hit by US President Donald Trump's tariffs following a slew of new threats to the bloc and other US trading partners, Bloomberg has reported. Ribera spoke from Beijing where she is visiting for two days of climate-focused talks with Chinese officials including Vice Premier Ding Xuexiang. Ribera's meeting comes as Trump ramps up pressure on trading partners in the final weeks of negotiations ahead of his so-called reciprocal tariffs. While she suggested the EU will keep negotiating, the bloc will work harder to sell its wares to other places if the tariffs become a reality. 'We need to keep on working to build resilience and to build partnerships with the other partners, the other allies in the world that are also open and willing to apply the rule of law,' said Ribera, an executive vice-president of the European Commission. That will 'ensure that peaceful and fair trade flows keep on taking place.' Her visit will be followed by a EU-China summit next week, when EU and Chinese leaders may touch on thorny issues spanning trade and geopolitics. China has sought closer ties with the EU, but the bloc has raised concerns about Chinese industrial overcapacity, lack of market access for EU firms and Beijing's support for Moscow after it invaded Ukraine. Other EU complaints include fresh export controls by China on rare earth magnets that have hit European industries. There's also been little progress in resolving differences over the EU's decision to impose tariffs on Chinese electric vehicles over claims producers have benefited from unfair subsidies. 'It should not be a bottleneck killing the possibility of prosperity all over the world,' Ribera said in reference to China's control over rare earths. 'So that is another bullet where we will still need to talk, to discuss to avoid harm.' In an interview after she spoke on Bloomberg TV, Ribera said it was 'still a little bit premature' to discuss a joint communique or declaration with China on climate cooperation but emphasized there was a shared willingness between Brussels and Beijing to deepen talks. The EU is reluctant to sign a joint declaration on climate action with China at a mid-July meeting because of concerns about the pace of emissions reduction by the world's top polluting nation, the FT reported last week. The newspaper cited EU's climate commissioner Wopke Hoekstra, who was quoted as saying China isn't doing enough to commit to faster cuts. With assistance from Lucille Liu, James Mayger, Josh Xiao and Adrian Wong. This article was generated from an automated news agency feed without modifications to text.